Novo Nordisk and University of Washington to collaborate on exploring the role of the brain in regulating blood glucose and obesity
- Details
- Category: Novo Nordisk
Novo Nordisk today announced that a research collaboration has been initiated with Dr Michael Schwartz, director of The Diabetes and Obesity Center of Excellence at UW Medicine. The collaboration aims to understand factors mediating brain control of blood glucose and appetite with the ultimate goal of developing new therapeutic agents for the treatment of diabetes and obesity.
Bristol-Myers Squibb to acquire Cardioxyl Pharmaceuticals, Inc.
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Cardioxyl Pharmaceuticals, Inc. announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the issued and outstanding capital stock of Cardioxyl, a private biotechnology company focused on the discovery and development of novel therapeutic agents for the treatment of cardiovascular disease.
'Science' says Abbott is a Top Employer
- Details
- Category: Abbott
The journal Science has recognized Abbott (NYSE: ABT) as a Top 20 Employer. The global healthcare company ranked No. 14 overall, receiving high marks for social responsibility, employee loyalty, and having a work culture that aligns with the values of its employees.
Allergan plc confirms discussions regarding potential business combination transaction with Pfizer Inc.
- Details
- Category: Financial
Allergan plc today confirmed that it has been approached by Pfizer Inc. and is in preliminary friendly discussions regarding a potential business combination transaction. Allergan stated that no agreement has been reached and there can be no certainty that these discussions will lead to a transaction, or as to the terms on which a transaction, if any, might be agreed.
Novartis Foundation and partners launch new hypertension program in Ghana
- Details
- Category: Novartis
The Novartis Foundation and its partners have begun screening patients in the Community-based Hypertension Improvement Project (ComHIP), a two-year program designed to evaluate the impact of an innovative healthcare model on hypertension management and control in Ghana.
FDA approves IMLYGICTM (talimogene laherparepvec) as first oncolytic viral therapy in the US
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for IMLYGICTM (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery.
Bristol-Myers Squibb reports third quarter financial results
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the third quarter of 2015, which were highlighted by strong global sales, key regulatory and clinical milestones in Immuno-Oncology and the completion of several business development transactions strengthening the company's diversified pipeline.
More Pharma News ...
- Roche delivers strong sales growth in the first nine months of 2015
- AstraZeneca and Lilly expand immuno-oncology research collaboration with new combinations
- Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma
- Kenya first country to launch 'Novartis Access', expanding affordable treatment options against chronic diseases
- Merck brand relaunched
- Bristol-Myers Squibb's Opdivo (nivolumab) receives expanded FDA approval in previously-treated metastatic non-small cell lung cancer (NSCLC)
- Roche's ocrelizumab first investigational medicine to show positive pivotal study results in both relapsing and primary progressive forms of multiple sclerosis